Rodrigo González-Ramírez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rodrigo González-Ramírez has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Gilberto Castañeda-Hernández
Departamento de Farmacología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Mexico City, Mexico
5 shared publications - Mara Medeiros
Unidad de Investigación y Diagnóstico en Nefrología y Metabolismo Mineral Óseo, Hospital Infantil de México Federico Gómez, Ciudad de México, Mexico
4 shared publications Ana María Hernández
Unidad de Investigación y Diagnóstico en Nefrología y Metabolismo Mineral Óseo, Hospital Infantil de México Federico Gómez, Ciudad de México, Mexico
2 shared publications- Lorena Medina-Aymerich
Duke Clinical Research Institute Durham North Carolina USA
2 shared publications - Pilar García-Roca
Unidad de Investigación y Diagnóstico en Nefrología y Metabolismo Mineral Óseo, Hospital Infantil de México Federico Gómez, Ciudad de México, Mexico
2 shared publications A. Esquivel
Departamento de Farmacologia, Centro de Investigación y de Estudios Avanzados el Instituto Politécnico Nacional, Mexico City, Mexico
1 shared publication
Latest Publications
- 1 November 2019
- Published by Taylor & Francis in Pharmaceutical Patent Analyst
- Vol. 8 (6) , 221-224
The challenges of developing and commercializing biosimilars in Latin America
- 1 November 2019
- Published by Taylor & Francis in Pharmaceutical Patent Analyst
- Vol. 8 (6) , 221-224
The challenges of developing and commercializing biosimilars in Latin America
- 1 October 2019
- Published by Wiley in Pediatric Transplantation
- Vol. 23 (8) , e13595
Limited sampling strategy to predict the area under the curve of tacrolimus in Mexican renal transplant pediatric patients receiving Prograf® or non‐innovator formulations
TDM of tacrolimus is usually performed with trough levels (C0h). However, in pediatric patients, C0h may not be an adequate marker. The AUC is considered a more suitable indicator of drug exposure. As several blood samples are needed for the estimation of AUC, and LSS for predicting tacrolimus AUC and optimizing the dose adjustment have been proposed. Moreover, in emerging countries such as Mexico, non‐innovator formulations, which bioequivalence has not been demonstrated, are frequently used. Hence, the aim of this study was to develop and validate a LSS to predict the tacrolimus AUC0‐12h in Mexican pediatric kidney transplant recipients who received either Prograf® or non‐innovator tacrolimus formulations. A total of 56 pharmacokinetic profiles were randomized into two groups: model development (n = 28) and model validation (n = 28). The limited sampling equations were obtained after a stepwise multiple regression using AUC as the dependent variable and tacrolimus blood concentrations, quantified by CMIA, at different time points as the independent variables. The final equation included observed concentrations at 1 hour (C1h) and 4 hours (C4h) after dose administration. The predictive performance of the model was adequate in terms of both, bias and precision. Results strongly suggest that the clinical use of this LSS could provide an ethical, cost‐, and time‐effective method in the TDM of tacrolimus in pediatric patients with kidney transplant. The model proved to be adequate with either Prograf® or non‐innovator tacrolimus formulations of dubious bioequivalence.
- 1 October 2019
- Published by Wiley in Pediatric Transplantation
- Vol. 23 (8) , e13595
Limited sampling strategy to predict the area under the curve of tacrolimus in Mexican renal transplant pediatric patients receiving Prograf® or non‐innovator formulations
TDM of tacrolimus is usually performed with trough levels (C0h). However, in pediatric patients, C0h may not be an adequate marker. The AUC is considered a more suitable indicator of drug exposure. As several blood samples are needed for the estimation of AUC, and LSS for predicting tacrolimus AUC and optimizing the dose adjustment have been proposed. Moreover, in emerging countries such as Mexico, non‐innovator formulations, which bioequivalence has not been demonstrated, are frequently used. Hence, the aim of this study was to develop and validate a LSS to predict the tacrolimus AUC0‐12h in Mexican pediatric kidney transplant recipients who received either Prograf® or non‐innovator tacrolimus formulations. A total of 56 pharmacokinetic profiles were randomized into two groups: model development (n = 28) and model validation (n = 28). The limited sampling equations were obtained after a stepwise multiple regression using AUC as the dependent variable and tacrolimus blood concentrations, quantified by CMIA, at different time points as the independent variables. The final equation included observed concentrations at 1 hour (C1h) and 4 hours (C4h) after dose administration. The predictive performance of the model was adequate in terms of both, bias and precision. Results strongly suggest that the clinical use of this LSS could provide an ethical, cost‐, and time‐effective method in the TDM of tacrolimus in pediatric patients with kidney transplant. The model proved to be adequate with either Prograf® or non‐innovator tacrolimus formulations of dubious bioequivalence.
- Open Access
- 18 April 2019
- Published by Grupo Anltyk S.A. de C.V. in Latin american journal of clinical sciences and medical technology
- Vol. 3 (1) , 128-134
Comparison between enzyme-multiplied immunoassay technique (EMIT) and high-performance liquid chromatography with ultraviolet detection (HPLC-UV) for the therapeutic drug monitoring of mycophenolic acid in Mexican pediatric patients with renal transplantation
Introduction. Mycophenolic acid (MPA) is an immunosuppressant; thus, monitoring of plasma levels is recommended. The most popular analytic methods used for the MPA quantification are the enzyme-multiplied immunoassay technique (EMIT) and the high-performance liquid chromatography with ultraviolet detection (HPLC-UV). The purpose of the present study was to compare both methods performances for the therapeutic drug monitoring of MPA in Mexican pediatric patients with renal transplantation. Material and Methods. A prospective cross‐sectional study was carried out, 25 patients with kidney transplantation were included. Mycophenolate mofetil was administered and blood samples were drawn at 0, 0.5, 1, 2, 3, 4, 6, 8, and 12 h after medication. Plasma samples were obtained and divided into two aliquots for further quantification by both methodologies. Each concentration determined by EMIT was compared with the corresponding quantification by HLPC-UV. Bias and precision were estimated as previously described by Sheiner and Beal. Results. EMIT overestimated MPA concentrations with a positive bias of 59.25% and a precision of 54.85%. AUC0-12, the recommended parameter for therapeutic drug monitoring of MPA, was significantly overestimated by EMIT in more than 50%. Discussion. Overestimation derives from metabolite cross-reactivity in EMIT, which does not occur with HPLC-UV. Hence, HPLC-UV appears to be a more suitable method for MPA therapeutic drug monitoring in Mexican pediatric patients with renal transplantation.
- 18 April 2019
- Published by Grupo Anltyk S.A. de C.V. in Latin american journal of clinical sciences and medical technology
- Vol. 3 (1) , 128-134
Open AccessComparison between enzyme-multiplied immunoassay technique (EMIT) and high-performance liquid chromatography with ultraviolet detection (HPLC-UV) for the therapeutic drug monitoring of mycophenolic acid in Mexican pediatric patients with renal transplantation
Introduction. Mycophenolic acid (MPA) is an immunosuppressant; thus, monitoring of plasma levels is recommended. The most popular analytic methods used for the MPA quantification are the enzyme-multiplied immunoassay technique (EMIT) and the high-performance liquid chromatography with ultraviolet detection (HPLC-UV). The purpose of the present study was to compare both methods performances for the therapeutic drug monitoring of MPA in Mexican pediatric patients with renal transplantation. Material and Methods. A prospective cross‐sectional study was carried out, 25 patients with kidney transplantation were included. Mycophenolate mofetil was administered and blood samples were drawn at 0, 0.5, 1, 2, 3, 4, 6, 8, and 12 h after medication. Plasma samples were obtained and divided into two aliquots for further quantification by both methodologies. Each concentration determined by EMIT was compared with the corresponding quantification by HLPC-UV. Bias and precision were estimated as previously described by Sheiner and Beal. Results. EMIT overestimated MPA concentrations with a positive bias of 59.25% and a precision of 54.85%. AUC0-12, the recommended parameter for therapeutic drug monitoring of MPA, was significantly overestimated by EMIT in more than 50%. Discussion. Overestimation derives from metabolite cross-reactivity in EMIT, which does not occur with HPLC-UV. Hence, HPLC-UV appears to be a more suitable method for MPA therapeutic drug monitoring in Mexican pediatric patients with renal transplantation.
- Open Access
Biosimilars in rheumatology: what the clinician should know
Biosimilars are now a reality in rheumatology. Although analytical and non-clinical procedures to establish similarity have evolved significantly, clinical trials demonstrating equivalent efficacy and safety are absolutely required for all biosimilars. The design of such trials, including equivalence and non-inferiority statistical approaches, are discussed. Clinical evidence on biosimilars that have been approved recently or are presently being developed for use in rheumatology is also reviewed and contrasted with that available for biomimics (or intended copies), which are non-innovator biologics that are marketed in several countries but have not undergone review according to a regulatory pathway for biosimilars.
Open AccessBiosimilars in rheumatology: what the clinician should know
Biosimilars are now a reality in rheumatology. Although analytical and non-clinical procedures to establish similarity have evolved significantly, clinical trials demonstrating equivalent efficacy and safety are absolutely required for all biosimilars. The design of such trials, including equivalence and non-inferiority statistical approaches, are discussed. Clinical evidence on biosimilars that have been approved recently or are presently being developed for use in rheumatology is also reviewed and contrasted with that available for biomimics (or intended copies), which are non-innovator biologics that are marketed in several countries but have not undergone review according to a regulatory pathway for biosimilars.
- 13 March 2015
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 54 (10) , 1083-1090
A Compartmental Analysis for Morphine and Its Metabolites in Young Children After a Single Oral Dose
Currently, the majority of the surgical procedures performed in paediatric hospitals are done on a day care basis, with post-operative pain being managed by caregivers at home. Pain after discharge of these post-operative children has historically been managed with oral codeine in combination with paracetamol (acetaminophen). Codeine is an opioid, which elicits its analgesic effects via metabolism to morphine and codeine-6-glucuronide. Oral morphine is a feasible alternative for outpatient analgesia; however, the pharmacokinetics of morphine after oral administration have been previously described only sparsely, and there is little information in healthy children.
- 13 March 2015
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 54 (10) , 1083-1090
A Compartmental Analysis for Morphine and Its Metabolites in Young Children After a Single Oral Dose
Currently, the majority of the surgical procedures performed in paediatric hospitals are done on a day care basis, with post-operative pain being managed by caregivers at home. Pain after discharge of these post-operative children has historically been managed with oral codeine in combination with paracetamol (acetaminophen). Codeine is an opioid, which elicits its analgesic effects via metabolism to morphine and codeine-6-glucuronide. Oral morphine is a feasible alternative for outpatient analgesia; however, the pharmacokinetics of morphine after oral administration have been previously described only sparsely, and there is little information in healthy children.
- 30 June 2014
- Published by Wiley in Pediatric Transplantation
- Vol. 18 (6) , 568-574
Bioavailability of a generic of the immunosuppressive agent mycophenolate mofetil in pediatric patients
The use of generic immunosuppressive agents is controversial, especially for the treatment of pediatric patients, as information on the bioavailability of generic immunosuppressants in children is particularly scarce. The aim of the study was to compare the bioavailabilities of two products containing mycophenolate mofetil, the innovator and a generic, in children. Pediatric patients with end‐stage renal disease on the waiting list for renal transplantation received a single oral dose of mycophenolate mofetil as either the innovator product (CellCept®, Roche) or the generic (Tevacept®, Teva Pharmaceuticals). A nine point pharmacokinetic profile was obtained. Mycophenolic acid concentration was quantitated in plasma by HPLC, plasma concentration‐against‐time curves were constructed, and bioavailability parameters were determined. Pharmaceutical quality analysis of both formulations, including drug content and dissolution profile, was also performed. There were no statistically significant differences between formulations in bioavailability parameters. Interindividual variability was very important, but individual values of AUC, an indicator of the extent of drug absorption, were within the same range for both formulations. The two formulations exhibited similar drug content and dissolution profiles, as well as comparable mycophenolic acid plasma levels in an end‐stage renal failure population.
- 30 June 2014
- Published by Wiley in Pediatric Transplantation
- Vol. 18 (6) , 568-574
Bioavailability of a generic of the immunosuppressive agent mycophenolate mofetil in pediatric patients
The use of generic immunosuppressive agents is controversial, especially for the treatment of pediatric patients, as information on the bioavailability of generic immunosuppressants in children is particularly scarce. The aim of the study was to compare the bioavailabilities of two products containing mycophenolate mofetil, the innovator and a generic, in children. Pediatric patients with end‐stage renal disease on the waiting list for renal transplantation received a single oral dose of mycophenolate mofetil as either the innovator product (CellCept®, Roche) or the generic (Tevacept®, Teva Pharmaceuticals). A nine point pharmacokinetic profile was obtained. Mycophenolic acid concentration was quantitated in plasma by HPLC, plasma concentration‐against‐time curves were constructed, and bioavailability parameters were determined. Pharmaceutical quality analysis of both formulations, including drug content and dissolution profile, was also performed. There were no statistically significant differences between formulations in bioavailability parameters. Interindividual variability was very important, but individual values of AUC, an indicator of the extent of drug absorption, were within the same range for both formulations. The two formulations exhibited similar drug content and dissolution profiles, as well as comparable mycophenolic acid plasma levels in an end‐stage renal failure population.
- 1 January 2010
- Published by Elsevier in Transplantation Proceedings
- Vol. 42 (1) , 353-356
Comparison of Dissolution Properties of 2 Enteric-Coated Formulations Containing Mycophenolate Sodium: Myfortic vs Femulan
- 1 January 2010
- Published by Elsevier in Transplantation Proceedings
- Vol. 42 (1) , 353-356
Comparison of Dissolution Properties of 2 Enteric-Coated Formulations Containing Mycophenolate Sodium: Myfortic vs Femulan